following a resubmission:
mifamurtide (Mepact) is accepted for use within NHS Scotland.
Indication under review: in combination with post-operative multi-agent chemotherapy for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults. Safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.
Mifamurtide has been shown to increase overall survival compared with multi-agent chemotherapy alone in patients aged up to 30 years with newly-diagnosed resectable osteosarcoma.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of mifamurtide. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland.
Download detailed advice146KB (PDF)
Medicine details
- Medicine name:
- mifamurtide (Mepact)
- SMC ID:
- 621/10
- Indication:
- For the treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 08 August 2011